• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …

Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

BACKGROUND: Device-detected atrial fibrillation (also known as subclinical atrial fibrillation
or atrial high-rate episodes) is a common finding in patients with an implanted cardiac …

Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Valvular heart disease (VHD) is common and poses important challenges from the
standpoints of diagnosis and therapeutic management. Clinical practice guidelines have …

Stroke is a devastating condition with significant morbidity and mortality worldwide.
Antithrombotic therapy plays a crucial role in both primary and secondary prevention of …

Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for …

Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …

It is a sad reality that although eminently preventable, and despite possessing such
knowledge for> 70 years, rheumatic heart disease (RHD) remains the most common cause …